Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles

Human Reproduction

Volumn 22, Issue 6, 2007, Pages 1657-1661

  Isikoglu, M ^a   Ozdem, S ^a   Berkkanoglu, M ^a   Jamal, H ^a   Senturk, Z ^a   Ozgur, K ^a  

^a Antalya IVF   (Turkey)

Author keywords

GnRHa; ICSI; Leuprolide; Long protocol

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; LEUPRORELIN; LUCRIN DAILY; LUCRIN DEPOT; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ABORTION; ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOPHYSIS FUNCTION; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METAPHASE; NIDATION; OOCYTE; OVARY HYPERSTIMULATION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRANSVAGINAL ECHOGRAPHY;

EID: 34447300181     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem054     Document Type: Article

References (32)

1. Albuquerque LE, Saconato, H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2002;3:CD002808.
2. Allahbadia GN, Kadam K, Gandhi G et al. The impact of low dose depot Leuprolide Acetate administration in ART patients - a multicentric study. 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM). 16-20 mOctober, 2004, (oral abstract presentation).
3. Balaban B, Urman B, Isiklar A et al. The effect of pronuclear morphology on embryo quality parameters and blastocyst transfer outcome. Hum Reprod 2001;16:2357-2361.
4. Balasch J, Gomez F, Casamitjana R et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod 1992;7:1230-1234.
5. Ben-Rafael Z, Lipitz S, Bider D et al. Ovarian hyporesponsiveness in combined gonadotrophin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 1991;55:272-275.
6. Caspi E, Ron-El R, Golan A et al. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotrophin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotrophins. Fertil Steril 1989;51:95-99.
7. Chang M-Y, Chiang C-H, Hsieh T-T et al. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69:505-510.
8. Chappel S, Howles C. Reevaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-1212.
9. Dal Prato L, Borini A, Trevisi MR et al. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: A randomized study. Hum Reprod 2001;16:1409-1414.
10. Dal Prato L, Borini A, Coticchio G et al. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: A randomized study. Hum Reprod 2004;19:2200-2205.
11. Daya S. Long versus short gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. The Cochrane Library, issue 3, Update Software, Oxford, 1999.
12. Devreker F, Govaerts I, Bertrand E et al. The long-acting gonadotrophin-releasing hormone analogs impaired the implantation rate. Fertil Steril 1996;65:122-126.
13. Doldi N, Persico P, De Santis L et al. Serum progesteroni at human chorionic gonadotrohin injection significantly correlate with femali age. Minerva Ginecol 2005;57:477-482.
14. El-Nemr A, Bhide M, Khalifa Y et al. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynecol Reprod Biol 2002;103 140-145.
15. Fleming R, Lloyd F, Herbert M et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13 1788-1792.
16. Fujii S, Sato S, Fukui A et al. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod 2001;16:1671-1675.
17. Geber S, Sales L, Sampaio MA. Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: A clinical endocrinological study of the ovarian response. J Assist Reprod Genet 2002;19 313-318.
18. Hsieh Y, Tsai H, Chang C et al. Comparison of a single half-dose, long-acting form of gonadotrophin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. Fertil Steril 2000;73 817-820.
19. Liu H, Lai Y, Davis O et al. Improved pregnancy outcome with gonadotrophin releasing hormone agonist stimulation is due to the improvement in oocyte quantity rather than quality. J Assist Reprod Genet 1992;9:338-342.
20. Loumaye E, Engrand P, Howles C et al. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997;67:889-899.
21. Messinis IE, Templeton A, Baird DT. Endogenous luteinizing hormone surge during superovulation induction with sequential use of clomiphene citrate and pulsatile human menopausal gonadotrophin. J Clin Endocrinol Metab 1985;61:1076-1080.
22. Messinis IE, Templeton A, Baird DT. Endogenous luteinizing hormone surge in women during induction of multiple follicular development with pulsatile follicle stimulating hormone. Clin Endocrinol 1986;24 193-201.
23. Oyesanya OA, Teo SK, Quah E et al. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: A comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact. Hum Reprod 1995;10:1042-1044.
24. Ozcakir HT, Levi R, Tavmergen E. Premature luteinization defined as progesterone levels > 1 on hCG administration day seems to adversely affect clinical Otcome in long gonadotrophin releasing hormone agonist cycles. J Obstet Gynaecol Res 2004;30:100-104.
25. Parinaud J, Beaur A, Bourreau E et al. Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril 1998; 50:597-602.
26. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 1994;41:485-504.
27. Shechter A, Lunenfeld A, Potashnik G et al. The significance of serum progesterone levels on the day of hCG administration on IVF pregnancy rates. Gynecol Endocrinol 1994;8:89-94.
28. Tesarik J, Sousa M. Key elements of a highly efficient intracytoplasmic sperm injection technique: Ca2 + fluxes and oocyte cytoplasmic dislocation. Fertil Steril 1995;64:770-776.
29. Tsai HD, Chen CM, Lo HY et al. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod 1995;10 2909-2912.
30. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-1008.
31. Yim SF, Lok IH, Cheung LP et al. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod 2001;16:492-494.
32. Zanagnolo V, Dharmarajan AM, Hesla J et al. Effects of a gonadotrophin-releasing hormone analog on rabbit ovarian function. Endocrinology 1996;137:5400-5406.